Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era-Reference-Cited by-同舟云学术

Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era

Published:2020-01-30 Issue:2 Volume:38 Page:137-145
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Sesques Pierre¹^ORCID,Bourcier Jessie²,Golfier Camille³,Lebras Laure⁴,Nicolas‐Virelizier Emmanuelle⁴,Hacini Maya⁵,Perrin Marie Claire⁶,Voillat Laurent⁷,Bachy Emmanuel¹,Traverse‐Glehen Alexandra⁸,Moreau Anne⁹,Martin Laurent¹⁰,Ramla Selim¹⁰,Casasnovas Olivier³,Le Gouill Steven¹¹,Salles Gilles¹,Ghesquières Hervé¹

Affiliation:

1. Department of Hematology, Centre Hospitalier Lyon Sud Université Claude Bernard Lyon 1 Pierre‐Bénite France

2. Department of Hematology Nantes University Hospital, CHU of Nantes and CHD Vendée La Roche‐sur‐Yon France

3. Department of Hematology Dijon University Hospital Dijon France

4. Department of Hematology Centre Léon Bérard Lyon France

5. Department of Hematology Centre Hospitalier Métropole Savoie Chambéry France

6. Department of Hematology Centre Hospitalier Fleyriat Bourg‐en‐Bresse France

7. Department of Hematology Centre Hospitalier of Chalon‐sur‐Saône Chalon‐sur‐Saône France

8. Department of Pathology, Centre Hospitalier Lyon Sud Université Claude Bernard Lyon 1 Pierre Bénite France

9. Department of Pathology CHU of Nantes Nantes France

10. Department of Pathology Dijon University Hospital Dijon France

11. Department of Hematology, CHU of Nantes CRCINA INSERM team 10 Nantes Nantes University NUN Next Nantes France

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2713

Reference38 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

4. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

5. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma;Journal of International Medical Research;2024-02

2. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis;BMC Cancer;2023-01-23

3. Indolent Lymphomas;The EBMT/EHA CAR-T Cell Handbook;2022